A reduction of viral mRNA, proteins and induction of altered morphogenesis reveals the anti-HTLV-1 activity of the labdane-diterpene myriadenolide in vitro

BMC Microbiology

Edel Figueiredo Barbosa-Stancioli³  Elaine Maria de Souza-Fagundes⁴  Carlos Leomar Zani⁵  Margareth Spangler Andrade⁶  Rodrigo Gonçalves Silva dos Santos³  Flavio Guimaraes Da Fonseca¹  Jaqueline Gontijo de Souza³  Luciana Debortoli de Carvalho³  Marina Lobato Martins²  Orlando Abreu Gomes⁷  Camila Pacheco Silveira Martins³ 

[1] Laboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, Belo Horizonte, 6627, Minas Gerais, Brazil;Serviço de Pesquisa, Fundação HEMOMINAS, Belo Horizonte, Minas Gerais, Brazil;Interdisciplinary HTLV Research Group – GIPH - Fundação HEMOMINAS, Belo Horizonte, Minas Gerais, Brazil;Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;Centro de Pesquisas Renè Rachou, FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil;Centro Tecnológico SENAI CETEC, Belo Horizonte, Minas Gerais, Brazil;Núcleo de Ciências Exatas – FACE – Universidade FUMEC, Belo Horizonte, Minas Gerais, Brazil

关键词: ATL;    HAM/TSP;    Antiviral activity;    Diterpene myriadenolide;    HTLV-1;   

Others  :  1090247
DOI  :  10.1186/s12866-014-0331-2

 received in 2014-07-02, accepted in 2014-12-17,  发布年份 2014

【 摘 要 】

Background

Human T-lymphotropic virus 1 (HTLV-1) has been associated with leukemia/lymphoma (ATL) and myelopathy/tropical spastic paraparesis (HAM/TSP), in addition to other inflammatory diseases as well as infection complications. Therapeutic approaches for HTLV-1-related pathologies are limited. The labdane diterpene myriadenolide (AMY) is a natural product that exhibit biological activities, such as anti-inflammatory and antiviral activity as reported for HIV and herpesvirus.

Results

We demonstrated that this natural product was able to inhibit the expression of gag-pol mRNA and substantially reduced the expression of the structural proteins p19 and gp46. Comparison of treated and untreated cells shows that AMY alters both the morphology and the release of viral particles. The Atomic Force Microscopy assay showed that the AMY treatment reduced the number of particles on the cell surface by 47%.

Conclusion

We demonstrated that the labdane diterpene myriadenolide reduced the expression of the structural proteins and the budding of viral particles, besides induces altered morphogenesis of HTLV-1, conferring on AMY a new antiviral activity that may be useful for the development of new compounds with specific anti-HTLV-1 activity.

【 授权许可】

   
2014 Martins et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci 1982, 79:2031-2035.
• [2]Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M: HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1:1031-1032.
• [3]Watanabe T: HTLV-1-associated diseases. Int J Hematol 1997, 66:257-278.
• [4]Gout O, Baulac M, Gessain A, Semah F, Saal F, Périès J: Rapid development of myelopathy after HTLV-1 infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990, 322:383-388.
• [5]Gillet N, Carpentier A, Barez PY, Willems L: WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL?Retrovirology 2012, 9:115.
• [6]Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009, 27:453-459.
• [7]Bazarbachi A, Hermine O: Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(Suppl 1):186-190.
• [8]Tanaka A, Takeda S, Kariya R, Matsuda K, Urano E, Okada S, Komano J: A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia 2013, 27:1621-1627.
• [9]Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G, Alvarez C, Talledo M, Gotuzzo E, de Almeida KR, Galvão-Castro B, Vandamme AM, Van Weyenbergh J: Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy.PLoS Negl Trop Dis 2012, 6:e1729.
• [10]Yamano Y, Sato T: Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.Front Microbiol 2012, 3:389.
• [11]Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M: Therapeutic trials in 200 patients with HTLV-I-associated myelopa-thy/tropical spastic paraparesis. J Neurovirol 1996, 2:345-355.
• [12]Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M: Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double- blind, controlled trial. Neurologyl 1996, 46:1016-1021.
• [13]Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Butman JA, Dambrosia J, Leist TP, McFarland H, Jacobson S: Interferon-b1a therapyin humanT-lymphotropic virus type I- associated neurologic disease. Ann Neurol 2005, 57:526-534.
• [14]Cragg GM, Boyd MR, Khanna R, Kneller R, Mays TD, Mazan KD, Newman DJ, Sausville EA: International collaboration in drug discovery and development: the NCI experience. Pure Appl Chem 1999, 71:1619-1633.
• [15]Verpoorte R: Exploration of nature’s chemodiversity: the role of secondary metabolites as leads in drug development. Drug Develop Trends 1988, 3:232-238.
• [16]Verpoorte R: Pharmacognosy in the new millennium: leadfinding and biotechnology. J Pharm Pharmacol 2000, 52:253-262.
• [17]Balunas MJ, Kinghorn AD: Drug discovery from medicinal plants. Life Sci 2005, 78:431-441.
• [18]Sadqui M, Fushman D, Munoz V: Atom–by–atom analysis of global downhill protein folding. Nature 2006, 442:317-321.
• [19]Fernandez MA, Tornos MP, Garcia MD, de las Heras B, Villar AM, Saenz MT: Anti-inflammatory activity of abietic acid, a diterpene isolated from Pimenta racemosa var. grissea. J Pharm Pharm Sci 2001, 53:867-872.
• [20]Navarro A, de las Heras B, Villar A: Immunomodulating properties of diterpene andalusol. Planta Med 2000, 66:289-291.
• [21]Singh M, Pal M, Sharma RP: Biological activity of the labdane diterpenes. Planta Med 1999, 65:2-8.
• [22]Dimas K, Demetzos C, Marsellos M, Sotiriadou R, Malamas M, Kokkinopoulos D: Cytotoxic activity of labdane type diterpenes against human leukemia cell lines in vitro. Planta Med 1998, 64:208-211.
• [23]Zani C, Alves TMA, Queiroz R, Fontes ES, Shin YG, Cordell GA: A cytotoxic diterpene from Alomia myriadenia. Phytochem 2000, 53:877-880.
• [24]Souza-Fagundes EM, Gazzinelli G, Parreira GG, Martins-Filho AO, Amarante-Mendes GP, Correa-Oliveira R, Zani CL: In vitro activity of labdane diterpene from Alomia myriadenia (Asteraceae): immunosuppression via induction of apoptosis in monocytes. Int Immunopharmacol 2003, 3:383-392.
• [25]Ayisi NK, Gupta SV, Qualtiere LF: Modified tetrazolium-based calorimetric method for determining the activities of anti-HIV compounds. J Virol Methods 1991, 33:335-344.
• [26]Cook LB, Elemans M, Rowan AG, Asquith B: HTLV-1: persistence and pathogenesis. Virol 2013, 435:131-140.
• [27]Ohyoshi T, Funakubo S, Miyazawa Y, Niida K, Hayakawa I, Kigoshi H: Total synthesis of (-)-13-oxyingenol and its natural derivative. Angew Chem Int Ed Engl 2012, 51:4972-4975.
• [28]Pan LL, Fang PL, Zhang XJ, Ni W, Li L, Yang LM, Chen CX, Zheng YT, Li CT, Hao XJ, Liu HY: Tigliane-type diterpenoid glycosides from Euphorbia fischeriana. J Nat Prod 2011, 74:1508-1512.
• [29]Khan MT, Ather A, Thompson KD, Gambari R: Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res 2005, 67:107-119.
• [30]Satou Y, Matsuoka M: Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. Rev Med Virol 2013, 5:269-280.
• [31]Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L: The HTLV-1 Tax interactome.Retrovirology 2008, 5:76.
• [32]Satou Y, Matsuoka M. Molecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis.Leuk Res Treatment 2012, 213653.
• [33]Simonis N, Rual JF, Lemmens I, Boxus M, Hirozane-Kishikawa T, Gatot JS, Dricot A, Hao T, Vertommen D, Legros S, Daakour S, Klitgord N, Martin M, Willaert JF, Dequiedt F, Navratil V, Cusick ME, Burny A, Van Lint C, Hill DE, Tavernier J, Kettmann R, Vidal M, Twizere JC: Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses.Retrovirology 2012, 9:26.
• [34]Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003, 299:1713-1716.
• [35]Majorovits E, Nejmeddine M, Tanaka Y, Taylor GP, Fuller SD, Bangham CR: Human T-lymphotropic virus-1 visualized at the virological synapse by electron tomography.PLoS One 2008, 3:e2251.
• [36]Delamarre L, Pique C, Rosenberg AR, Blot V, Grange MP, Le Blanc I, Dokhélar MC: The Y-S-L-I tyrosine-based motif in the cytoplasmic domain of the human T-cell leukemia virus type 1 envelope is essential for cell-to-cell transmission. J Virol 1999, 73:9659-9663.
• [37]Le Blanc I, Blot V, Bouchaert I, Salamero J, Goud B, Rosenberg AR, Dokhélar MC: Intracellular distribution of human T-cell leukemia virus type 1 Gag proteins is independent of interaction with intracellular membranes. J Virol 2002, 76:905-911.
• [38]Grigsby IF, Zhang W, Johnson JL, Fogarty KH, Chen Y, Rawson JM, Crosby AJ, Mueller JD, Mansky LM: Biophysical analysis of HTLV-1 particles reveals novel insights into particle morphology and Gag stochiometry.Retrovirology 2010, 7:75.
• [39]Fogarty KH, Zhang W, Grigsby IF, Johnson JL, Chen Y, Mueller JD, Mansky M: New insights into HTLV-1 particle structure, assembly, and Gag-Gag interactions in living cells. Viruses 2011, 3:770-793.
• [40]Li M, Kannian P, Yin H, Kesic M, Green PL: Human T lymphotropic virus type 1 regulatory and accessory gene transcript expression and export are not rex dependent. AIDS Res Hum Retroviruses 2012, 28:405-410.
• [41]Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL: Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator. J Virol 2004, 78:11077-11083.
• [42]Li M, Kesic M, Yin H, Yu L, Green PL: Kinetic analysis of human T-cell leukemia virus type 1 gene expression in cell culture and infected animals. J Virol 2009, 83:3788-3797.
• [43]Calabrese EJ: Hormetic mechanisms. Crit Rev Toxicol 2013, 43:580-606.
• [44]Calabrese EJ. Hormesis: from mainstream to therapy.J Cell Commun Signal. 2014. Nov 1. [Epub ahead of print] PubMed PMID: 25366126.
• [45]Cornelius C, Koverech G, Crupi R, Di Paola R, Koverech A, Lodato F, Scuto M, B Salinaro AT, Cuzzocrea S, Calabrese EJ, Calabrese V: Osteoporosis and alzheimerpathology: role of cellular stress response and hormetic redox signaling in aging and bone remodeling.Front Pharmacol 2014, 10:120.
• [46]Severson W, McDowell M, Ananthan S, Chung DH, Rasmussen L, Sosa MI, White LE, Noah J, Colleen B: High-throughput screening of a 100,000 compound library for inhibitors of influenza A virus (H3N2). J Biomol Screen 2008, 13:879-887.
• [47]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
• [48]Li M, Green PL: Detection and quantification of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR. J Virol Methods 2007, 142:159-168.
• [49]Coelho-dos-Reis JG, Martins-Filho OA, de Brito-Melo GE, Gallego S, Carneiro-Proietti AB, Souza JG, Barbosa-Stancioli EF: GIPH: Performance of IgG and IgG1 anti-HTLV-1 reactivity by an indirect immunofluorescence flow cytometric assay for the identification of persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy. J Virol Methods 2009, 160(1–2):138-148.